OBE 022

Drug Profile

OBE 022

Alternative Names: OBE-022

Latest Information Update: 24 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck Serono
  • Developer Merck Serono; ObsEva
  • Class Small molecules; Tocolytics
  • Mechanism of Action Prostaglandin F2 alpha antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Preterm labour

Most Recent Events

  • 31 Dec 2017 Phase-II clinical trials in Preterm labour in Finland (PO)
  • 14 Nov 2017 ObsEva submits IND to begin the phase IIa PROLONG trial for Preterm labour, prior to November 2017
  • 15 Aug 2017 ObsEva plans phase IIa PROLONG trial for Preterm labour in fourth quarter of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top